Le principali pubblicazioni dei dottori della fondazione ARCO di Cuneo sono reperibili al sito http://www.ncbi.nlm.nih.gov/pubmed.
Le Pubblicazioni
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Posted on 17 dicembre 2014
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C.
Oral Oncol. 2012 Jul;48(7):602-7. doi: 10.1016/j.oraloncology.2012.01.022. Epub 2012 Feb 21.
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.
Posted on 17 dicembre 2014
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse. Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T. Br J Cancer. 2012 Aug 7;107(4):732-8. doi: 10.1038/bjc.2012.308. Epub 2012 […]
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
Posted on 17 dicembre 2014
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook […]
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study
Posted on 17 dicembre 2014
Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.
Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.
Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells
Posted on 17 dicembre 2014
Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.
Anticancer Drugs. 2013 Feb;24(2):120-30. doi: 10.1097/CAD.0b013e328358d1dc.
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
Posted on 17 dicembre 2014
Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O’Neil K, Roncaroli F, Crook T.
Cell Death Dis. 2013 Jan 17;4:e458. doi: 10.1038/cddis.2012.197.
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma
Posted on 17 dicembre 2014
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T. J Invest Dermatol. 2013 […]
The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
Posted on 17 dicembre 2014
Invest New Drugs. 2013 Oct;31(5):1107-14. doi: 10.1007/s10637-013-0005-1. Epub 2013 Aug 4.
The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer.
Denaro N, Nigro CL, Russi EG, Merlano MC.
Onco Targets Ther. 2013 Sep 16;9:1231-41. doi: 10.2147/OTT.S46545. Review.
Role of IL-8 induced angiogenesis in uveal melanoma
Posted on 10 dicembre 2014
Role of IL-8 induced angiogenesis in uveal melanoma. Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Lo Nigro C. Invest New Drugs. 2013 Oct;31(5):1107-14. doi: 10.1007/s10637-013-0005-1. Epub 2013 Aug 4. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Denaro N, Nigro CL, Russi EG, […]
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma
Posted on 10 dicembre 2014
Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.
Int J Biol Markers. 2013 Dec 17;28(4):e336-47. doi: 10.5301/jbm.5000041.